Summit Therapeutics Expands Ivonescimab Program With GSK Collaboration

An update from Summit Therapeutics ( (SMMT) ) is now available.

On January 12, 2026, Summit Therapeutics presented at the 44th Annual J.P. Morgan Healthcare Conference and disclosed that it had submitted a Biologics License Application in the fourth quarter of 2025 to the U.S. Food and Drug Administration for ivonescimab in combination with chemotherapy as a second-line or later treatment for patients with epidermal growth factor receptor-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer, underscoring a key regulatory milestone for its lead asset in the U.S. market. On the same date, the company announced a clinical trial collaboration with GSK to evaluate ivonescimab in combination with GSK’s investigational B7-H3–targeting antibody-drug conjugate risvutatug rezetecan across multiple solid tumor settings, including small cell lung cancer, a move that expands ivonescimab’s development footprint and strengthens Summit’s strategic positioning in global oncology through high-profile partnerships and broader combination-therapy opportunities for cancer patients.

The most recent analyst rating on (SMMT) stock is a Hold with a $18.00 price target. To see the full list of analyst forecasts on Summit Therapeutics stock, see the SMMT Stock Forecast page.

Spark’s Take on SMMT Stock

According to Spark, TipRanks’ AI Analyst, SMMT is a Neutral.

The score is held back primarily by weak financial performance—deepening losses and faster cash burn—despite low current leverage. Offsetting this, clinical and regulatory momentum from the latest earnings call (strong Phase III data and planned BLA submission) plus supportive financing/events improve the outlook, while technicals and valuation signals remain broadly neutral.

To see Spark’s full report on SMMT stock, click here.

More about Summit Therapeutics

Summit Therapeutics is a biotechnology company focused on oncology, developing innovative immunotherapy and biologic treatments, with a core emphasis on ivonescimab, a dual anti-VEGF/anti-PD-1 investigational antibody being advanced through multiple Phase III trials and commercialized in partnership with Akeso in China, where it has received approvals and has been used by tens of thousands of patients. The company positions itself as a frontrunner in the PD-1 x VEGF class, targeting serious unmet medical needs across various solid tumors, including non-small cell lung cancer and other difficult-to-treat cancer indications.

Average Trading Volume: 2,825,388

Technical Sentiment Signal: Hold

Current Market Cap: $14.02B

For a thorough assessment of SMMT stock, go to TipRanks’ Stock Analysis page.